

## **PRESS RELEASE**

# **Hemcheck receives order from university hospital in Regensburg**

Hemcheck Sweden AB has received an order from UKR, the university hospital in Regensburg. The order is a small first order regarding bgs-Test and refers to diagnostic use. The University Hospital in Regensburg is a large hospital in eastern Bavaria with over 800 hospital beds.

- It is very positive that we are getting new hospitals as customers and especially university hospitals, which are important reference customers. We hope that this is the start of a longer collaboration with UKR, says Joen Averstad, CEO of Hemcheck.

### **For further information contact:**

Hemcheck Sweden AB (publ)  
Joen Averstad, CEO  
Tel: +46 76 108 8191  
Email: [joen.averstad@hemcheck.com](mailto:joen.averstad@hemcheck.com)

### **About Hemcheck**

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, [info@fnca](mailto:info@fnca.se), is the Certified Adviser to the company.